Beovu Experience UZ Leuven
Launched by UNIVERSITAIRE ZIEKENHUIZEN KU LEUVEN · Jan 21, 2022
Trial Information
Current as of May 14, 2025
Unknown status
Keywords
ClinConnect Summary
Brolucizumab (Beovu, Novartis, Basel, Switzerland) is the newest anti-vascular endothelial growth factor (anti-VEGF) drug. It received FDA approval for the treatment of neovascular age-related macular degeneration (nAMD) in October 2019 followed by EMA approval in February 2020. Brolucizumab received marketing approval based on the two pivotal phase 3 clinical trials - HAWK and HARRIER - with a q8/q12 week dosing regimen. Potential benefits of brolucizumab are assumed to be related to its low molecular weight with subsequent better tissue penetration as well as higher molar concentration. T...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Diagnosis of neovascular age-related macular degeneration
- • 2. Partial response on current anti-VEGF treatment or unability to prolong the treatment interval beyond 6 or 8 weeks
- Exclusion Criteria:
- • 1. Any form of previous intraocular inflammation 2. Any form of previous inflammatory reaction after anti-VEGF treatment 3. Functionally monophthalmic patients 4. Any sign of active intraocular inflammation
About Universitaire Ziekenhuizen Ku Leuven
Universitaire Ziekenhuizen KU Leuven is a leading academic medical center in Belgium, renowned for its commitment to advancing healthcare through innovative research and clinical excellence. Affiliated with KU Leuven, one of Europe’s premier universities, the institution integrates cutting-edge scientific inquiry with high-quality patient care. It plays a pivotal role in the development and implementation of clinical trials, fostering collaboration between researchers, healthcare professionals, and industry partners to translate scientific discoveries into effective treatments. The hospital's multidisciplinary approach ensures comprehensive patient safety and ethical standards, positioning it as a trusted sponsor in the realm of clinical research.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Leuven, , Belgium
Patients applied
Trial Officials
Julie Jacob, MD
Principal Investigator
Universitaire Ziekenhuizen KU Leuven
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials